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Abstract
Tick-borne encephalitis virus is the causative agent of tick-borne encephalitis, a potentially fatal neurological infection. Tick-
borne encephalitis virus belongs to the family of flaviviruses and is transmitted by infected ticks. Despite the availability of
vaccines, approximately 2000–3000 cases of tick-borne encephalitis occur annually in Europe for which no curative therapy
is available. The antiviral effects of RNA mediated interference by small interfering RNA (siRNA) was evaluated in cell culture
and organotypic hippocampal cultures. Langat virus, a flavivirus highly related to Tick-borne encephalitis virus exhibits low
pathogenicity for humans but retains neurovirulence for rodents. Langat virus was used for the establishment of an in vitro
model of tick-borne encephalitis. We analyzed the efficacy of 19 siRNA sequences targeting different regions of the Langat
genome to inhibit virus replication in the two in vitro systems. The most efficient suppression of virus replication was
achieved by siRNA sequences targeting structural genes and the 39 untranslated region. When siRNA was administered to
HeLa cells before the infection with Langat virus, a 96.5% reduction of viral RNA and more than 98% reduction of infectious
virus particles was observed on day 6 post infection, while treatment after infection decreased the viral replication by more
than 98%. In organotypic hippocampal cultures the replication of Langat virus was reduced by 99.7% by siRNA sequence
D3. Organotypic hippocampal cultures represent a suitable in vitro model to investigate neuronal infection mechanisms and
treatment strategies in a preserved three-dimensional tissue architecture. Our results demonstrate that siRNA is an efficient
approach to limit Langat virus replication in vitro.
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Introduction
Tick-borne encephalitis virus complex represents a group of
closely related viruses endemic in Europe and Asia causing serious
neuroinfections and hemorrhagic fevers [1]. Tick-borne enceph-
alitis virus (TBEV) belong to the Flaiviridae family and can be
divided in three main subtypes, the European, the Siberian and
Far Eastern subtypes [2]. TBEV are transmitted to humans by the
bite of infected ticks and, in rare cases, through the consumption of
infected unpasteurized milk [3,4]. Following an incubation period
of 3–8 days after a tick bite, the virus replicates locally in
epidermal dendritic cells and spreads via lymph vessels to the
blood stream where a short but significant viremia occurs and
extraneural tissues are infected. It is during this viremic phase that
the virus crosses the blood-brain barrier and invades the central
nervous system (CNS) by a still unknown mechanism. Once the
virus has reached the CNS, active infection causes inflammation,
lysis of cells and cellular dysfunction [5,6]. Clinical manifestations
of TBEV infections typically follow a biphasic course. The first
viremic phase is characterized by flu-like symptoms such as fever,
headache and muscle pain. After 3–7 days of an asymptomatic
phase, 20–30% of the patients develop the second meningoen-
cephalitic phase with neurological disorders of varying severity
[5,7,8,9]. The most common clinical feature of TBE patients is
ataxia followed by paresis or paralysis of one or more extremities
[10].
Two efficient formalin-inactivated whole virus vaccines are
available in Europe and provide a high degree of protection
against the disease. Nevertheless more than 2500 TBE cases have
been registered yearly in Europe in the past ten years and
a continuous increase in TBE morbidity was observed in the last
years [11,12]. Up to today no specific therapeutic options are
available for flaviviral infections and an effective therapy for
TBEV infection would be highly desirable [13]. Results from in
vitro and in vivo studies indicate that therapeutics based on RNA
interference (RNAi) could be effective against viral infections, and
small interfering RNA (siRNA) molecules are promising candi-
dates for future clinical applications [14,15,16,17]. Indeed, several
RNAi-based antiviral drugs are currently being tested in clinical
trials [18,19,20,21].
RNA interference is a conserved post-transcriptional gene
silencing process which leads to the specific degradation of RNA
within the cytoplasm of eukaryotic cells [22,23,24]. Long double-
stranded RNA molecules are initially processed by the enzyme
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Dicer into 21–25 nucleotides long small interfering RNA. In the
cytoplasm siRNAs are incorporated into the multiprotein RNA-
induced silencing complex (RISC) which results in sequence
specific association and degradation of the complementary mRNA
[24,25]. SiRNA mediated intervention strategies take advantage of
this conserved mechanism by artificially introducing siRNA
molecules into the cytoplasm which ultimately leads to the
degradation of target RNA molecules. It was shown that the
application of siRNA molecules with sequences complementary to
viral genomic RNA or RNA replication intermediates allows to
significantly reduce the number of virus progeny in infected cells.
Using this strategy the replication of human pathogenic flavi-
viruses such as West Nile virus (WNV), Dengue virus (DENV) and
Japanese encephalitis virus (JEV) was successfully inhibited both in
vitro and in vivo [14,26,27,28,29,30] and recently inhibition of
TBEV by RNAi was demonstrated in human embryonic kidney
cells (HEK293T) [31]. Sensitive target sequences were identified
within the structural (Capsid (C), membrane protein (M) and
envelope (E)), non-structural (mostly NS5 and NS3) and the 39
untranslated region of the flavivirus 11 kb open reading frame
(ORF).
We used organotypic hippocampal brain slice cultures (OHCs)
infected with Langat virus (LGTV) as a model to analyze the
effectiveness of RNAi in the inhibition of the virus replication.
OHCs is a well established model based on in vitro cultured brain
slices which was adapted for this virus encephalitic model from
previous work [32]. Organotypic cultures offer unique advan-
tages over other in vitro models, in that they reproduce important
aspects of the in vivo situation. Organotypic cultures retain the
three-dimensional tissue architecture of the brain with a preserved
cellular composition including neurons, microglial cells and
astrocytes [32,33]. The use of OHCs allowed the culture of
Langat virus in an in vitro system reproducing some aspects of
TBEV infection of the brain. LGTV is a member of the tick-
borne encephalitis virus complex sharing high nucleotide
homology with TBEV. It has an attenuated virulence for the
human host and was used as a vaccine candidate against TBE
for several years, but was abandoned due to the sporadic
occurrence of encephalitis cases (1:18000) [34,35]. Because of its
relative avirulence for humans it can be handled under BSL-2
conditions. LGTV retains neurovirulence for rodents and is
therefore considered a suitable virus-model for the pathogenic
TBEV in mice and rats [36,37,38,39]. Using Langat virus in the
organotypic brain culture model we could demonstrate the
effectiveness of siRNA in inhibiting TBE virus replication in
a three-dimensional neuronal tissue architecture.
Results
Evaluation of siRNA Sequences Targeting Langat Virus
Genome
A total of 19 siRNA sequences (Q1–Q6 and D1–D13) targeting
genes within the structural (S), the non-structural (NS) and the 39
and 59 untranslated regions (UTRs) of Langat genome (Table 1
and Figure 1 A) were tested. All siRNA sequences were evaluated
for their capacity to inhibit replication of Langat virus in HeLa
cells when transfected 4 h before the infection occurred. Fourteen
out of the 19 specific siRNA sequences were able to induce
a significant reduction of viral genome copy numbers in
comparison to the nonsense siRNA used as a negative control
(Figure 1B).
Inhibition of virus replication was most efficient with siRNA
molecules targeting sequences located within the structural region
(Q5, Q6, D5, D12) and the 59 UTR (D3 and D8), reducing viral
genome copy numbers by up to 85%. Only Q1, D1 and D10, all
targeting the 39 UTR, had no effect on virus replication. A
comparative analysis of all siRNA target sequences with the
genomes of five members of the Tick-borne encephalitis virus
complex revealed that siRNA sequences D1, D3, D8, D10 and
D13 located within the 39UTR, 59UTR and the core region were
strongly conserved with 1 to 2 nucleotide divergence between
different viral subtypes. SiRNA sequence D3 was the only one
with 100% sequence identity in all three TBEV subtypes and in
the Omsk hemorrhagic fever virus (Table S1). SiRNA sequence
D3 targeting 59UTR was selected for further experiments on
HeLa cells and organotypic cultures.
Inhibition of Virus Replication by siRNA D3 in HeLa Cells
To determine the inhibitory effect of siRNA sequence D3 over
time the replication profile of Langat virus was assessed daily
during the 6 days incubation period in cells treated with specific
siRNA D3 and in cells treated with nonsense siRNA as controls.
While virus replication was continuous in HeLa cells treated with
nonsense siRNA, the number of viral genome copies was reduced
by 96.5% (1.4 logs) (Figure 2A) and the number of infectious
particles by 98.8% (2 logs) (Figure 2B), from day 2 to day 6 post
infection in cells transfected with siRNA D3. To exclude
unspecific inhibition of virus replication trough an effect of the
transfection reagent on cell viability we performed a LDH-based
cytotoxicity assay on cells under the different treatment regimes.
No significant difference in cytotoxicity was observed between
transfected and infected cells and untransfected and uninfected
cells demonstrating that cell viability was comparable between
the four groups (Figure S1).
We analyzed the effectiveness of siRNA on viral replication
when administered after the initiation of the infection. To this end
HeLa cells were first infected with Langat virus at MOI of 10, 1,
0.1 or 0.01 and 1 h later transfected with siRNA sequence D3.
Compared to cells transfected with the nonsense siRNA sequence,
treatment of infected HeLa cells with siRNA sequence D3 resulted
in a reduction of viral genome copies by 1.6 log (MOI of 10),
2.4 log (MOI of 1), 2.4 log (MOI = 0.1) and 5 log (MOI = 0.01),
respectively which corresponds to an inhibition of more than 98%
for all the infectious doses. At the lowest infectious dose of
0.01 MOI the virus titer was reduced below the detection limit
(Figure 3).
Langat Virus Replication in the Organotypic
Hippocampal Cell Culture Model
OHCs are an excellent model for the investigation of neuronal
infection mechanisms and new treatment strategies. The ability of
Langat virus to infect and replicate in OHCs was demonstrated by
real-time RT-PCR and immunofluoresence (Figure 4). Using a red
fluorescent antibody, cells expressing Langat virus proteins were
specifically stained. Figure 4 A shows a strong expression pattern
of viral proteins in OHC infected with Langat virus in contrast to
uninfected OHC depicted in Figure 4 B. Co-staining of Langat
virus proteins (red) and Fox 3 (green), a marker for neuronal cells,
shows strong co-localisation, especially in the cornu ammonis (CA)
and dentate gyrus (DG) (Figure 4 C, D, E, F, G, H).
Antiviral Activity of siRNA in Infected Organotypic
Hippocampal Cell Cultures
To assess the capacity of siRNA to inhibit virus replication in
a complex three-dimensional neuronal network, inhibition experi-
ments were performed on OHCs. Transfection of OHCs with the
specific siRNA sequence D3 before and after the infection led to
SiRNA Inhibits Langat Virus in Brain Slice Culture
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an efficient inhibition of virus replication reducing the number of
viral genome copies in OHC homogenates from 5.4610E5 to
1.7610E3 copies/ml (2.7 logs) and the number of infectious
particles from 2.7610E2 to an average of 0.5 ffu/ml (4.3 logs)
(Figure 5 A and B) corresponding to a reduction of more than
99.6% as compared to nonsense siRNA treated OHCs. No
Figure 1. LGTV-specific siRNA sequences inhibit production of viral RNA in HeLa cells. Nineteen siRNA sequences (Q1–Q6 and D1–D13)
targeting genes within the whole open reading frame of LGTV genome were analyzed for their antiviral potential on HeLa cells (A). After transfection
with siRNA, cells were infected with Langat virus (MOI = 10) and six days later virus replication was assessed by quantitative real-time RT-PCR (B).
Results are shown as a percentage of virus inhibition compared to the control cells transfected with the non-coding siRNA. Data are presented as
mean 6 SD of three independent experiments. Fourteen (Q2, Q3, Q4, Q5, Q6, D3, D4, D5, D6, D8, D9 D11 D12 and D13) out of 19 were significantly
reduced (p,0.05) compared to a theoretical mean of 100% expressed by cells treated with nonsense siRNA; measured by One sample t test.
doi:10.1371/journal.pone.0044703.g001
Table 1. Antisense sequences and positions of siRNAs used for inhibition.
Name Sequence Nt Position (59 –39) Genome region
Q1 59 – UAUAACGCCCAGUUCGGCCUU –39 10730 39UTR
Q2 59 – UUGACGGAACGAACCAGGCUG –39 5688 NS3
Q3 59 –UUGAGUUCACUACUCCGGCAU–39 3159 NS1
Q4 59 – UAGUAUGACCAGCCGCCUCUG –39 7912 NS5
Q5 59 – UUAGAUGAUACUUAGUUCCCT –39 1800 Env
Q6 59 – UCUGAUGACACUGUGAACGAG –39 1459 Env
D1 59 – UUUCUCUCUUCCCUCCUCCUU –39 10777 39UTR
D2 59 – UCAUCCACAGACUUUGAUCUU –39 3047 NS1
D3 59 – UUUCUCAACACGUUCACGAUU –39 83 59UTR
D4 59 – AUGCUCAUGUGUCUUGUCCUU –39 1576 Env
D5 59 – UUCUGCAAGGCCUAGUUCCUU –39 1970 Env
D6 59 – UUCCACUCCAAUCAUGAACUU –39 2857 NS1
D7 59 – AUAUCCACAAUCACAGUCGUU –39 47 59UTR
D8 59 – AUUCCCAGCUCUUGUUCUCUU –39 114 59UTR
D9 59 – AAUCCAUCCACCAUCAACCUU –39 897 pre M
D10 59 – UUUCCCGUCACCACUCUCAUU –39 10651 39UTR
D11 59 – UCUCCCUCGAGCCAUUGGUUU –39 795 pre M
D12 59 – UUUAGAACGGCCUUCCCGGUU –39 135 Core
D13 59 – AAGUCCAUUUGGCAUUUGGUU –39 223 Core
doi:10.1371/journal.pone.0044703.t001
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difference in cytotoxicity was observed by assessing LDH release
between transfected OHCs and controls (Figure S2). The marked
reduction of viral progeny in organotypic cultures treated with
siRNA was confirmed by immunostaining methods. While in
OHCs transfected with the non-targeting siRNA the expression of
viral proteins led to strong red fluorescent signal in a high
percentage of the cells, in OHCs transfected with the specific
siRNA sequence D3 no red fluorescence was detectable, confirm-
ing an efficient reduction of viral protein levels in all cells (Fig. 5 C
and D).
Off-target Effects
Several studies suggest that transfection of cells with siRNAs
may result in the activation of the interferon pathway and affect
virus replication via interferon mediated antiviral activity
[40,41,42]. To investigate whether the treatment of OHCs with
siRNA leads to the activation of the IFN system, expression levels
of IFN-b mRNA were quantified by real time RT-PCR in non-
infected OHCs treated with different siRNA sequences and
compared to untreated or poly I:C treated cultures. While
treatment of HeLa cells with poly I:C, used as a positive control,
leds to a strong upregulation of IFN-b mRNA, none of the siRNA
sequences lead to an increase in the IFN-b mRNA expression 24 h
after the second transfection (Figure S3).
Discussion
Therapeutic options for the treatment of TBE are lacking and
specific therapies are urgently needed since the incidence of TBE
is rising. Several studies have shown that siRNA molecules have
the potential to be used as a specific therapeutic strategy against
viral infections. Due to difficulties in delivery, toxicity and the
stimulation of unspecific immune response few approaches were
continued in vivo. For TBE virus infections detailed investigations
determining optimal target sequence and inhibitory capacity for
synthetic siRNA are lacking. The majority (11/19) of the 19
siRNA sequences screened in this study were capable of reducing
Langat virus titer by more than 80% in comparison to nonsense
siRNA when transfected into the cells before the infection (Figure 1
B). The most effective reduction in viral replication was achieved
with siRNA sequences targeting the 39 UTR and the structural
genes. SiRNA sequence D3 (59UTR) and Q6 (Envelope) showed
the highest capacity to inhibit viral replication, reducing the
number of viral RNA genome copies from 1610E6/ml (nonsense
siRNA) to 5.5610E4/ml (siRNA D3) and 6.6610E4/ml (siRNA
Q6) respectively, corresponding to a reduction of more than 93%
(Figure 1 B). In addition to its strong antiviral activity sequence D3
is highly conserved between different members of the tick-borne
encephalitis virus complex and was therefore selected for further
experiments on HeLa cells and organotypic brain cultures. Using
the siRNA sequence D3 we could demonstrate that the application
of siRNA after the infection was still effective. In fact the inhibitory
effect was comparable to the results obtained when siRNA was
applied before infection. These results indicate that it is feasible, at
least in the paradigm tested herein, to inhibit replication of TBEV
in vitro once the infection has been initiated.
For further in vitro analysis we developed an encephalitis model
based on infection of rat organotypic hippocampal brain cultures
with Langat virus. The use of an attenuated virus strain has several
advantages compared to the work with human pathogenic TBE
strains. Despite its relative avirulence for the human host, LGTV
shares a high nucleotide homology with pathogenic TBEV.
Nevertheless, LGTV can be handled under BSL-2 conditions. In
rodents Langat virus is able to cause viremia, infect the central
nervous system and thereby causing encephalitis and neuronal
lesions replicating clinical and histopathological features observed
in human cases of TBE [36,43]. Our immunohistochemical results
about infection of neuronal cells by LGTV is in agreement with
previous findings of fatal TBE human cases where neurons
represent the main target for TBEV infection [44]. By measuring
virus replication in organotypic hippocampal cultures and staining
Figure 2. Inhibitory effects of siRNA D3 on viral replication on
HeLa cells over time. The replication profile for Langat virus was
determined for the time period of 6 days. Indicated are the numbers of
RNA copies (A) and the number of infectious particles (B) for cell
cultures treated with nonsense siRNA or specific siRNA D3.
doi:10.1371/journal.pone.0044703.g002
Figure 3. Antiviral effect of siRNA D3 in relation to the
infectious dose of Langat. HeLa cells were infected with Langat
virus at different infectious dose (MOI of 10, 1, 0.1 or 0.01) and one hour
after infection, cells were treated with 200 nM siRNA sequence D3 or
with nonsense siRNA. Virus titer was assessed by quantitative real-time
RT-PCR 6 days after infection in the cell culture supernatant. The
reduction of viral RNA in siRNA D3 treated cells is statistically significant
compared to nonsense siRNA treated cells for all four MOI (p,0.05). The
data are presented as mean 6 SD of three independent experiments
and significance calculated using an unpaired T-test.
doi:10.1371/journal.pone.0044703.g003
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viral proteins within the neuronal cells we could demonstrate that
Langat virus productively infects neurons of rat brain slices
(Figure 4C, D, E, F, G, H). In many aspects OHCs fill the gap
between dissociated cell cultures and in vivo animal experiments.
OHCs are ex vivo brain slices and constitute an intact neuronal
network with a well-preserved representation of the most
Figure 4. Expression of Langat virus proteins in infected organotypic hippocampal cultures. OHCs were infected with 2610E6 FFU
Langat virus for 7 days and immunostained with an anti-Langat virus antibody (LGTV; red) (A). Uninfected slices are shown as a control (B). Double
staining of viral proteins (LGTV; red) (D 106; G 406) and neurons (FOX3; green) (E 106; H 406) on infected OHCs showed colocalisation (C 106; F
406). Cell nuclei were counterstained with Dapi (blue).
doi:10.1371/journal.pone.0044703.g004
SiRNA Inhibits Langat Virus in Brain Slice Culture
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important brain cells, including neurons, astrocytes and microglia
[45,46]. This in vitro model of neuronal network allows the
investigation of the mechanisms underlying neuropathogenicity of
TBE and, as we have shown in this study, the efficiency of new
antiviral drugs under conditions resembling those encountered in
vivo [47,48]. Our results obtained in OHCs transfected with the
siRNA sequence D3 support findings from several in vivo studies
showing that neuronal cells could be transfected with siRNA and
are competent to develop a strong siRNA mediated antiviral
activity [14,30,49,50]. Applying siRNA sequence D3 on organo-
typic cell cultures an inhibition of Langat virus replication by more
than 99.6% was achieved, both on the level of viral RNA and on
the number of infectious particles. After entering the human body,
tick-borne flaviviruses develop a high viremia which is considered
to be a prerogative for the subsequent invasion of the CNS [51].
The antiviral potential of our siRNA sequences may help to
attenuate the viremia and thus prevent the development of
encephalitis or, if encephalitis is already established, to limit the
number of infected neurons to a minimum thereby minimizing the
damage in the brain caused by either the virus itself or the immune
response to the infection.
The siRNA sequence D3 targets a well conserved stretch of the
59UTR of Langat virus sharing 100% homology with all 3
subtypes of TBEV, the European, the Siberian and the Far
Eastern subtype as well as with the Omsk hemorrhagic fever virus
and 95% (18 nucleotides out of 19) with Louping ill virus (see
Table S1). We therefore consider D3 a promising candidate for
future in vivo studies on TBEV infections. Other siRNA sequences
such as D5, D8, D12, D4, Q5 and Q6 were also highly effective in
our in vitro analysis and may be used in the combination with D3.
As it has been suggested in other studies the combination of 2 or
more specific siRNAs simultaneously targeting multiple viral
genome regions may enhance the inhibitory effect and reduce an
eventual viral escape [27,52].
An unspecific stimulation of the interferon response by the
siRNA sequence D3 is unlikely since no upregulation of the IFN-
b gene was detected. Cationic lipid reagents, such as Lipofecta-
mine RNAiMAX and Dharmafect 2 used in this study, are
promising carriers for the siRNA delivery in vivo [53,54]. However
they are known to cause side effects such as cytotoxicity and non-
specific activation of intracellular signalling pathways [55,56]. To
determine toxicity of the transfection regimen the LDH release
was assessed in several experiments but no increase in LDH level
was observed in HeLa cells or in organotypic cell cultures treated
with the transfection reagents and siRNA.
Despite these encouraging results, development of reliable
transfection methods remains the biggest hurdle in the progress of
in vivo antiviral RNAi-based drug therapies. In case of encepha-
litogenic viruses such as TBEV, carriers for therapeutic siRNA
molecules must be able to cross the blood-brain barrier [57]. For
these reasons the development of new strategies which allow highly
efficient transfection of siRNA molecules is a crucial step on the
Figure 5. Antiviral effect of RNAi on rat organotypic hippocampal cultures. OHC were transfected with 800 nM specific siRNA D3 or with
nonsense siRNA 24 h before and 1 h after the infection with LGTV. OHC were incubated for 6 days and virus titer assessed. The number of genome
copies (A) and the number of infectious particles (B) measured in OHCs pre- and posttreated with siRNA D3 or nonsense siRNA are indicated.
Expression of viral proteins was analyzed by immune staining of Langat virus proteins (red) in microtome slices of OHCs treated with specific siRNA
D3 (D) or with nonsense siRNA (C). Cell nuclei were stained with Dapi (blue). Figures C and D are representative images of six independent
experiments.
doi:10.1371/journal.pone.0044703.g005
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way towards the clinical use of RNAi-based therapies. Organo-
typic cultures represent a valuable tool to evaluate the efficiency of
different transfection strategies with siRNA and to determine their
potential to induce the interferon system in a conserved neuronal
network.
In summary, our study provides further support for the use of
RNAi technology in the development of antiviral drugs against
encephalitogenic tick-borne flaviviruses. Organotypic brain cul-
tures were used for the first time as a successful in vitro approach in
an RNAi-based antiviral therapy.
Materials and Methods
Cell Culture and Virus Amplification
Vero and HeLa cells were cultured in Eagle’s minimum
essential medium (MEM) supplemented with 10% foetal bovine
serum, 1.25% L-Glutamin, 1% Non-essential amino acids, 1%
Penicillin-Streptomycin and 0.5% Neomycin-Bacitracin (Bio-
chrom AG, Berlin, Germany). Langat virus strain TP21 was
kindly provided by Daniel Ru˚zˇek (University of South Bohemia,
Cˇeske´ Budeˇjovice, Czech Republic). Virus was cultured on 80%
confluent Vero cells in 75-cm2 culture flasks (Sigma-Aldrich,
Buchs, Switzerland) and grown for 7 days at 37uC in cell culture
medium containing 2% FBS. Virus containing cell culture
supernatant was titrated and used for infection and transfection
assays.
Immunoperoxidase Focus Assay (IPFA)
Virus quantification was performed by IPFA. Serial dilutions of
virus cultures (100 ml/well) were inoculated on 24 well plates with
80% confluent Vero cells. Viral adsorption was allowed for 1 h at
37uC on a rocking platform and wells overlaid with 200 ul of pre-
warmed cell culture medium (2% FBS) and 500 ul MEM
containing 1% methylcellulose (Sigma-Aldrich), 5% FBS, 1.25%
L-Glutamin, 1% Non-essential amino acids, 1% Penicillin-
Streptomycin and 0.5% Neomycin-Bacitracin. Plates were in-
cubated for 6 days at 37uC. Cells were washed with PBS pH 7.4,
fixed with 4% formaldehyde in PBS for 1 h and cell membrane
permeabilized by adding 1% Triton in PBS for 5 min. Following
two washing steps with PBST (PBS +0.05% Tween), 500 ml
monoclonal anti-flavivirus antibody (Anti-Flavivirus Group A
clone D1-4G2-4-15, Millipore AG, Switzerland) diluted 1:1000
in blocking buffer (PBST containing 10% FBS and 4% Skimmed
Milk powder (Hochdorf Nutritec AG, Sulgen, Switzerland)) was
added for 1 h at room temperature (RT). After two washing steps
with PBST cells were incubated for 1 h with the secondary goat
anti-mouse-HRP antibody (Anti-mouse IgG (H+L); Kirkegaard &
Perry Laboratories, Gaithersburg, USA) diluted 1:1000 in
blocking buffer. Viral spots were visualized after thorough washing
by adding the HRP substrate AEC (3-amino-9-ethylcarbozole)
(Fluka, Switzerland) in N,N-Dimethylformamide (Fluka, Switzer-
land) diluted in acetic acid 0.05 M (Fluka, Switzerland). Viral titers
were determined as focus forming units (FFUs) per millilitre.
Organotypic Cultures
Organotypic hippocampal cultures were prepared from 5 days-
old Wistar rats as previously described by us [33]. Briefly, rat pups
were sacrificed by a lethal dose of Pentobarbital i.p (G. Streuli &
Cie. SA, Uznach, Switzerland). The brain was removed and
submerged in ice-cold dissection medium consisting of Hank’s
balanced salt solution (HBSS; Gibco Life Technologies, Basel,
Switzerland) with 6 mg/ml glucose and 10 mg/ml Penicillin-
Streptomycin. Hippocampus was isolated and cut perpendicular to
the axis into 400 mm thick-sections by a McIlwain tissue chopper
(Mickle Laboratory, Giuldford, UK). Slices with intact hippocam-
pal morphology were selected and individually transferred on
a semiporous (0.4 mm) membrane of the Transwell inserts
(Corning Inc., Corning, NY). Inserts were placed in a 24-well
plate in contact with 200 ml serum-free Neurobasal TM medium
(Gibco) supplemented with B27 Supplement (20 ml/ml, Gibco).
Before transfection, slices were incubated at 37uC with 5% CO2
for 4 days. Medium containing B27 Supplement was changed
every day for the first two days.
siRNAs
Six siRNA sequences (Q1–Q6) were designed and synthesized
by Qiagen (Hilden, Germany) using the BioPredsi algorithm [58].
Thirteen sequences (D1–D13) (siSTABLE) were designed using
the Dharmacon online tool siDESIGN Center (http://www.
dharmacon.com/designcenter) and synthesized by the same
company (Thermo Fisher Scientific, Lafayette, USA). SiRNA
sequences were chosen according to the algorithm score.
Comparative analysis of all siRNA sequences with genomes of
tick-borne flaviviruses was performed using GeniusPro Version
5.5.7 (Table S1).
Transfection and Infection Assays
Transfection and infection experiments were performed on
HeLa cells and organotypic cell cultures. HeLa cells were seeded
to a confluency of 60–70% on 24-well plates the day before
transfection. When infection of HeLa cells was performed after
transfection, cells were first transfected with 200 nM siRNA for 4.
SiRNAs were complexed with the transfection reagent Lipofecta-
mine RNAiMAX (Invitrogen, Basel, Switzerland) according to the
manufacturer’s instructions and lipid-siRNA complexes added to
the cells with 1 ml of serum- and antibiotic-free MEM. After 4 h
incubation, cells were washed and infected with 200 ml Langat
virus in culture medium at MOI of 10. Virus inoculum was
removed after 1 h and cells were incubated with 1 ml antibiotic-
free MEM containing 2% FBS for 6 days. Virus titer was assessed
by determining the number of genome copies in 100 ml cell
supernatant by real-time RT-PCR and number of infectious
particles assessed by immunoperoxidase focus assay (IPFA).
When infection was performed before transfection, HeLa cells
were infected with Langat virus at a MOI of 10, 1, 0.1 or 0.01.
One hour after the infection the inoculum was removed and cells
were transfected with 200 nM siRNA/Lipofectamine RNAiMAX
complexes as described above. The siRNA/Lipofectamine com-
plexes were removed after 4 hours and cells incubated for 6 days at
37uC. Virus titer was assessed by determining the number of
genome copies in 100 ml cell supernatant by real-time RT-PCR 6
days after infection.
Organotypic hippocampal cultures were prepared as described
above. After slicing OHCs were cultured for 4 days to allow
recovery. OHCs were transfected with 800 nM siRNA complexed
with the lipid-based transfection reagent Dharmafect 2 (Thermo
Fisher Scientific, Lafayette, USA) for 24 h according to the
manufacturer’s instruction. Lipid-siRNA complexes were pre-
pared in 200 ml antibiotic-free Neurobasal Medium (NBM)
whereof 100 ml were given to the medium underneath the
membrane and 100 ml were added drop wise onto the slice. One
day after incubation the OHC were infected with 2610E6 FFU
Langat virus in 200 ml NBM. After 1 h inoculum was removed
and OHCs transfected for the second time. Viral genome copy
number and number of infectious particles were assessed 2 days
after the second transfection step.
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LDH Cytotoxicity Test
HeLa cells transfected with 200 nM siRNA (D3 or nonsense)
and untransfected cells were infected with Langat virus 4 h after
transfection and incubated for 6 days at 37uC. During 6 days
samples of 100 ml supernatant were taken daily and LDH activity
was quantified according to the manufacturer’s instructions
applying the Cytotoxicity Detection KitPLUS (LDH) (Roche
Diagnostics, Rotkreuz, Switzerland) by measuring optical density
(OD) at 490 nm.
Viral RNA Extraction
Nucleic acid extraction from cell supernatant or OHC
homogenate was performed using the BioRobot EZ1 Workstation
(Qiagen). 100 ml cell culture supernatant were inactivated in
400 ml AVL viral lysis buffer (Qiagen) and viral RNA isolated
applying the EZ1 Virus mini kit v2.0 (Qiagen). OHCs were
homogenized in 800 ml Qiazol (Qiagen) by the TissueLyser Sytem
(Qiagen) for 2 min at 25 Hz. Extraction was performed with the
Universal RNA Tissue Kit (Qiagen) following the manufacturer’s
instructions. RNA was eluted in a final volume of 50 ml.
Primers
The specific primers and probes for the detection of Langat
virus strain TP21 were designed using Primer Express software
v3.0 (Applied Biosystems, Foster City, CA) and purchased from
Microsynth (Balgach, Switzerland). LGTV forward primer 59-
TGTGTGGAGCGGCGATT-39; LGTV reverse primer 59-
TAAGGGCGCGTTCCATCTC-39; probe 59-AGC-
CACGCTTCCAGAGGAGCACC-39. Detection of interferon b,
OAS-2 and STAT-1 genes was performed using the correspond-
ing pre-designed QuantiTect Primer assays (Qiagen).
One Step Real-time Reverse Transcriptase PCR
Viral RNA was quantified by one-step real-time RT-PCR using
the QuantiFast probe RT-PCR kit (Qiagen) according to the
manufacturer’s protocol with the following cycling conditions:
reverse transcription at 50uC for 10 min, an initial PCR activation
step at 95uC for 5 min, 40 cycles of two-step cycling for 10 s at
95uC and 30 s at 60uC.
Fluorescence Microscopy
Organotypic hippocampal slices were fixed in 4% paraformal-
dehyde (PFA) in phosphate-buffered saline for 90 min at 4uC and
cryopreserved in 18% sucrose solution in PBS for 3–4 days. Slices
were cut into 12 mm thick sections with a Jung CM 1800 cryostat
(Leica Microsystems, Glattbrug, Switzerland) according to a pro-
cedure described elsewhere [33]. The sections were collected in
PBS, transferred to a chrome-alum-gelatine-coated glass slide, air
dried and kept in PBS. Organotypic sections were incubated with
primary antibodies directed against Langat virus (LGT-I-13A10;
1:1000 Fort Detrick, USAMRIID, USA) and FOX3 (rabbit
polyclonal; 1:1000, Millipore). Primary and secondary antibodies
were diluted in TBS (pH 7.6) containing 0.5% bovine serum
albumin. Sections were washed three times with PBS and then
exposed to the secondary antibody for 45 min at RT in the dark.
Secondary antibodies used were: donkey anti-mouse Cy3 (1:1000;
Jackson, West Grove, PA) and anti-rabbit Alexa Fluor 488
(1:1000; Invitrogen). After washing slides were counterstained with
Dapi for 1 min, washed and mounted with MowiolH (Merck,
Darmstadt, Germany) containing 2.5% DabcoH (Sigma-Aldrich).
Stained OHCs were photographed with a Zeiss fluorescent
microscope (Axiophot, Zeiss, West Germany).
Supporting Information
Figure S1 LDH release of HeLa cells as an index of
cytotoxicity over time. Transfected HeLa cells (siRNA D3 or
nonsense siRNA) infected with Langat virus compared to
untreated cells infected with Langat virus and to untreated and
uninfected cells used as negative control. Cytotoxicity results are
expressed as % LDH release of total LDH determined from
homogenized HeLa cells used as positive control.
(TIF)
Figure S2 LDH cytotoxicity assay on transfected orga-
notypic hippocampal cultures. OHCs transfected twice with
siRNA (D3 or nonsense), untransfected OHCs infected with
Langat virus or untreated OHCs were tested for cytotoxicity by
measuring LDH release in 100 ml of the medium surrounding the
slices 48 h after the second transfection. No difference in
cytotoxicity was measured between transfected and control groups.
Cytotoxicity results are expressed as % LDH release of total LDH
determined from homogenized OHCs used as positive control.
(TIF)
Figure S3 Expression level of IFN-b in transfected
OHCs. Expression levels of IFN-b mRNA was assessed in OHCs
treated with siRNA D3 or nonsense siRNA 48 h after the second
transfection and compared to IFN-b mRNA levels found in
untreated OHCs and in OHCs activated with poly I:C. Data
showed that transfection of OHCs did not result in upregulation of
IFN-b mRNA expression over the level of untreated slices. The
data are presented as the mean 6 SD from three independent
experiments.
(TIF)
Table S1 Comparative analysis of siRNA sequences
with members of the tick-borne encephalitis virus
complex.
(DOC)
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